The condition is “high-risk” plaque, once narrowly defined as plaque built up in the arteries that is likely to rupture, possibly leading to an acute heart attack or sudden cardiac death.

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...

Chinese researchers say they have developed a “cocktail” nanovaccine to prevent plaque from building up in the arteries – an underlying factor in heart disease, which is the leading cause of ...